Blood test to guide treatment for large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at whether a blood test can help doctors understand and monitor large B-cell lymphoma during treatment. It may help guide decisions about your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with diffuse large B-cell lymphoma or high-grade B-cell lymphoma.
- Your treatment plan includes standard chemo-immunotherapy (such as R-CHOP) that contains a CD20 antibody and an anthracycline.
- You are not planning to have maintenance therapy after your first round of treatment.
- You have not had prior treatment for this lymphoma, except for possibly local radiation.
- You do not have HIV-related lymphoma, other active cancers, or lymphoma that changed from a slower-growing type.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new High-grade B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.